Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2016 1
2017 1
2018 1
2019 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
2018 APLAR axial spondyloarthritis treatment recommendations.
Tam LS, Wei JC, Aggarwal A, Baek HJ, Cheung PP, Chiowchanwisawakit P, Dans L, Gu J, Hagino N, Kishimoto M, Reyes HM, Soroosh S, Stebbings S, Whittle S, Yeap SS, Lau CS. Tam LS, et al. Among authors: soroosh s. Int J Rheum Dis. 2019 Mar;22(3):340-356. doi: 10.1111/1756-185X.13510. Epub 2019 Feb 28. Int J Rheum Dis. 2019. PMID: 30816645
Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial.
Jamshidi A, Vojdanian M, Soroush M, Akbarian M, Aghaei M, Hajiabbasi A, Mirfeizi Z, Khabbazi A, Alishiri G, Haghighi A, Salimzadeh A, Karimzadeh H, Shirani F, Fard MRH, Nazarinia M, Soroosh S, Anjidani N, Gharibdoost F. Jamshidi A, et al. Among authors: soroosh s. Arthritis Res Ther. 2022 Jun 30;24(1):161. doi: 10.1186/s13075-022-02840-8. Arthritis Res Ther. 2022. PMID: 35773713 Free PMC article. Clinical Trial.
A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis.
Jamshidi A, Gharibdoost F, Vojdanian M, Soroosh SG, Soroush M, Ahmadzadeh A, Nazarinia MA, Mousavi M, Karimzadeh H, Shakibi MR, Rezaieyazdi Z, Sahebari M, Hajiabbasi A, Ebrahimi AA, Mahjourian N, Rashti AM. Jamshidi A, et al. Among authors: soroosh sg. Arthritis Res Ther. 2017 Jul 20;19(1):168. doi: 10.1186/s13075-017-1371-4. Arthritis Res Ther. 2017. PMID: 28728599 Free PMC article. Clinical Trial.
Performance of the 2010 Rheumatoid Arthritis Classification Criteria.
Davatchi F, Abari IS, Soroosh S, Soroosh M, Sadeghi Abdollahi B. Davatchi F, et al. Among authors: soroosh s. Int J Rheum Dis. 2012 Oct;15(5):455-61. doi: 10.1111/j.1756-185X.2012.01766.x. Epub 2012 Jun 12. Int J Rheum Dis. 2012. PMID: 23083035